Dasatinib Drugs Market Report 2026

The dasatinib drugs market size has grown strongly in recent years. It will grow from $1.53 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to approval of tyrosine kinase inhibitors for leukemia, increasing prevalence of chronic myeloid leukemia, clinical success of dasatinib in resistant cases, expansion of oncology treatment centers, availability of oral targeted therapies.

The dasatinib drugs market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growth in leukemia patient population, rising demand for personalized cancer treatment, increased penetration of generic oncology drugs, expansion of home-based cancer care, advancements in targeted drug development. Major trends in the forecast period include rising adoption of targeted cancer therapies, increasing use of oral oncology drugs, growing demand for generic dasatinib products, expansion of combination therapy approaches, improved patient adherence through oral formulations.

The rising prevalence of chronic myeloid leukemia (CML) is expected to drive the growth of the dasatinib drug market in the coming years. Chronic myeloid leukemia (CML) is a type of cancer affecting the bone marrow and blood, marked by the uncontrolled proliferation of abnormal white blood cells. The growing prevalence of CML is influenced by increased environmental exposures and lifestyle-related risk factors. The dasatinib drug market aids in disease management by targeting the BCR-ABL tyrosine kinase protein, which is responsible for the unchecked growth of leukemic cells. For example, in January 2023, the American Cancer Society (ACS), a US-based cancer-focused health organization, reported that CML cases in the United States rose to 8,930 in 2023, up from 8,860 cases in 2022. Consequently, the rising prevalence of chronic myeloid leukemia (CML) is fueling the expansion of the dasatinib drug market.

Major companies operating in the dasatinib drugs market are concentrating on developing generic versions to broaden market access, provide more affordable treatment options, and enhance availability for patients requiring long-term cancer therapy. Generic dasatinib medications are therapeutically equivalent formulations of the branded drug, delivering the same active ingredient, dosage, quality, and clinical effectiveness at a lower cost. This approach increases affordability, encourages competition, and reduces the financial burden on patients and healthcare systems. For example, in September 2024, Apotex Corp., a Canada-based pharmaceutical company, introduced the first generic version of Sprycel (dasatinib) in the United States for treating specific types of leukemia in adults and children, providing a high-quality, lower-cost alternative that improves treatment access and fosters competitive pricing within the dasatinib drugs market.

In January 2025, Handa Therapeutics, a US-based healthcare technology company, acquired PHYRAGO (dasatinib) tablets, an FDA-approved therapy for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, from Nanocopoeia, LLC, for an undisclosed sum. Through this acquisition, Handa Therapeutics intends to enhance its oncology portfolio and broaden its presence in the chronic myeloid leukemia (CML) therapeutics market. Nanocopoeia, LLC, is a US-based biopharmaceutical firm that focuses on developing and manufacturing a specialized formulation of the dasatinib drug.

Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Sun Pharmaceutical Industries Limited, Hetero Drugs Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Lupin Limited, MSN Laboratories Pvt. Ltd., Hikma Pharmaceuticals plc, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP.

North America was the largest region in the dasatinib drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dasatinib drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the dasatinib drugs market by increasing the cost of imported active pharmaceutical ingredients and key synthesis intermediates used in oncology drug manufacturing. These impacts are most evident among oncology drug manufacturers and hospital supply chains, particularly in regions that depend on cross border pharmaceutical sourcing. Rising tariff related input costs have contributed to higher production expenses and modest increases in treatment pricing. This has influenced procurement planning and reimbursement considerations in cancer care settings. However, tariffs are also encouraging domestic api manufacturing, local production of oncology drugs, and greater regional supply chain resilience over the long term.

The dasatinib drugs market research report is one of a series of new reports that provides dasatinib drugs market statistics, including dasatinib drugs industry global market size, regional shares, competitors with a dasatinib drugs market share, detailed dasatinib drugs market segments, market trends and opportunities, and any further data you may need to thrive in the dasatinib drugs industry. This dasatinib drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dasatinib drugs are a type of targeted therapy called tyrosine kinase inhibitors, mainly used to treat blood cancers, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). They function by inhibiting proteins that promote cancer cell growth, helping to slow the progression of the disease. This results in improved survival outcomes and more effective disease management.

The primary products in the dasatinib drugs market include tablets, oral suspension, and other forms. Dasatinib is mainly offered as tablets, providing patients with a convenient oral administration option. The drug is indicated for conditions such as chronic myeloid leukemia, acute lymphoblastic leukemia, and other diseases, with end users comprising hospitals, specialty clinics, and home healthcare providers.

The dasatinib drugs market consists of sales of sprycel and generic dasatinib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.